Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
July 2022
乾癬性関節炎における従来型抗リウマチ薬併用または非併用によるイキセキズマブの有効性と安全性: SPIRIT‑P1 と SPIRIT‑Pの3年結果
Clin Rheumatol. 2022 doi: 10.1007/s10067-022-06218-8
In this investigation ixekizumab showed sustained efficacy in PsA therapy for up to three years in both monotherapy and combination with MTX or a csDMARD. Here, investigators set out to evaluate the three-year efficacy and safety of ixekizumab with and without csDMARD use in patients with active PsA.
Keywords:
June 2020
バリシチニブの一時中断: 関節リウマチ患者における中断 の特徴と臨床アウトカムへの影響
Arth Res Ther 2020;22:115 doi.org/10.1186/s13075-020-02199-8
This study aimed to characterize temporary interruptions of baricitinib and describe their impact on efficacy and safety. Brief interruptions during phase 3 baricitinib trials were associated with minor increases in symptoms which were resolved following treatment. In life-long, chronic conditions such as RA, interruption of therapy is common for various reasons, such as side effects, non-compliance, or because a patient requires surgery. Concerns have been raised that these treatment breaks cou...
November 2018
従来型抗リウマチ薬またはグココルチコイドで治療中関節リウマチ患者のバリシチニブの安全性を有効性
Rheumatol Ther 2018 Dec;5(2):525-536. DOI 10.1007/s40744-018-0128-0
Baricitinib (BARI) in combination with MTX and concomitant csDMARDs was shown to be efficacious, regardless of corticosteroid use in RA patients. MTX is prescribed to most RA patients but concomitant csDMARDs and/or corticosteroids can be added. This study assessed the efficacy and safety of BARI in two arms; with/without corticosteroids and; with MTX only/MTX plus csDMARD/csDMARDs only. Baseline characteristics and adverse reactions were also compared. Data were pooled from two phase 3 studies ...